Thursday, July 9, 2009

Presidio Pharmaceuticals Adds $27M

San Francisco-based Presidio Pharmaceuticals said Thursday afternoon that it has raised another $27M for the firm. The company, which is focused on developing treatments for viral infections, including HIV-1 and HCV, said the round included New Leaf Venture Partners, Panorama Capital, Baker Brothers Investments, Ventures West Capital, Bay City Capital, Nexus Medical Partners and Sagamore BioVentures. The firm said the funding woul go towards advancing its HCV clinical candidate through clinical studies. Dr. Srinivas Akkaraju of New Leaf will join the board with the funding. The round brings the company's total raised to $54.5M. More information »